Everolimus

Belzutifan prolonged PFS compared with everolimus for certain patients with advanced renal cell carcinoma, according to topline data released by the agent’s manufacturer.

CHICAGO — In renal cell carcinoma, adjuvant everolimus improved recurrence-free survival after nephrectomy but narrowly missed the benchmark for statistical significance, according to final results from the phase 3 EVEREST study.

The combination of everolimus and itacitinib, an oral JAK inhibitor, was well-tolerated in patients with relapsed or refractory Hodgkin lymphoma, according to data presented at ASH Annual Meeting and Exposition.

SAN FRANCISCO — Among patients who underwent PCI for long lesions, IVUS-based guidance was associated with better outcomes than angiography-based guidance at 5 years, according to new data from the IVUS-XPL trial presented at TCT 2019.

As drug-eluting stent technology has evolved, stent thrombosis has become less of a risk and the standard recommendation of 1 year of dual antiplatelet therapy after PCI is being challenged, especially for patients at high bleeding risk.

SAN FRANCISCO — Among patients with CAD in the left main artery who underwent PCI, a biodegradable polymer everolimus-eluting stent plus 4 months of dual antiplatelet therapy conferred similar outcomes as a durable polymer EES plus 1 year of DAPT, according to results from the IDEAL-LM trial.

SAN FRANCISCO — The rate of adverse events at 5 years increased among patients assigned a bioresorbable vascular scaffold compared with those assigned an everolimus-eluting coronary stent system, according to new data from the ABSORB III trial presented at the Transcatheter Cardiovascular Therapeutics Scientific Symposium.

PARIS — Biodegradable polymer sirolimus-eluting stents were superior to durable polymer everolimus-eluting stents with regard to target lesion failure among patients with STEMI who underwent PCI, according to 1-year results of the BIOSTEMI trial presented at the European Society of Cardiology Congress.

Fulvestrant in combination with everolimus extended PFS significantly longer than fulvestrant with vistusertib or fulvestrant alone among women with hormone receptor-positive metastatic breast cancer, according to results of the randomized phase 2 MANTA trial published in JAMA Oncology.

In the overall cohort of a randomized trial, three drug-eluting stents were associated with similar rates of target vessel failure and stent thrombosis at 3 years.